samedan logo
 
 
 
spacer
home > ebr > winter 2003 > is resistance futile?
PUBLICATIONS
European Biopharmaceutical Review

Is Resistance Futile?

Resistance is futile, or so the battle cry of the new enemy of humans in Star Trek goes. However resistance is hardly futile in the case of the retrovirus HIV. To date, HIV has infected 42 million people worldwide. In 2002 there were five million new infections and three million people died as a result of HIV infection or its end result - acquired immune deficiency syndrome (AIDS). The latest figures suggest that one person worldwide is infected with HIV every 60 seconds and 70 per cent of the burden of the world's HIV epidemic is carried by sub-Saharan Africa.

Since HIV-1 was isolated in 1984 and the cause of AIDS discovered, the innovation in drug development has been unrelenting. HIV infects and destroys human CD4 receptor positive cells in human hosts. This destruction leads to a loss of the cellular immune response and thus a switch of the immune system from a TH1 response to a TH2 one. The destruction of CD4+ cells is caused by the assembly of new HIV virus particles and their final budding out of the infected cell.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr DC Herath, Senior Medical Advisor in HIV at Roche UK

Dr DC Herath completed his Medical Degree at St Mary's Hospital Medical School, London. During that time, Dr Herath also completed a BSc in Haematology, conducting a study into thrombophilic disorders in recurrent miscarriage women. Having graduated, he spent several years as SHO in the major specialities (Renal, Neurology, Cardiology, Gastroenterology, Respiratory and ID/HIV) all at St Mary's, and then worked as SpR in HIV at St Mary's before moving to Roche as Clinical Science Specialist on the TORO 2 study in February 2002. In June of this year, Dr Herath undertook the post of Senior Medical Advisor in HIV for the Roche UK affiliate, overseeing the whole HIV portfolio from a medical viewpoint. He is still a practising physician in HIV, with a patient list of 80 at St Mary's Hospital in London.

spacer
Dr DC Herath
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement